| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| J9271 |
Injection, pembrolizumab, 1 mg |
6,235 |
2,239 |
$24.20M |
| 77386 |
|
19,248 |
1,822 |
$19.85M |
| J9299 |
Injection, nivolumab, 1 mg |
3,997 |
1,299 |
$10.44M |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
2,275 |
1,989 |
$9.63M |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,996 |
1,361 |
$8.59M |
| 0510 |
|
206,116 |
174,710 |
$7.11M |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
4,605 |
4,537 |
$6.82M |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
3,712 |
1,060 |
$6.42M |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
1,540 |
988 |
$5.64M |
| J9035 |
Injection, bevacizumab, 10 mg |
2,551 |
987 |
$5.57M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
19,628 |
19,168 |
$4.06M |
| J2357 |
Injection, omalizumab, 5 mg |
2,280 |
1,368 |
$3.63M |
| 0450 |
Emergency room services |
51,728 |
45,893 |
$3.63M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
97,761 |
82,359 |
$3.23M |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
2,465 |
784 |
$3.14M |
| J2323 |
Injection, natalizumab, 1 mg |
2,534 |
709 |
$3.13M |
| J0897 |
Injection, denosumab, 1 mg |
2,838 |
1,684 |
$3.11M |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
16,083 |
15,786 |
$2.87M |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
6,665 |
6,601 |
$2.85M |
| J3490 |
Unclassified drugs |
127,918 |
56,782 |
$2.82M |
| 80053 |
Comprehensive metabolic panel |
244,457 |
193,858 |
$2.68M |
| J9312 |
Injection, rituximab, 10 mg |
739 |
333 |
$2.53M |
| J9306 |
Injection, pertuzumab, 1 mg |
2,186 |
412 |
$2.48M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
34,374 |
33,082 |
$2.42M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
31,147 |
27,710 |
$2.22M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
9,713 |
9,565 |
$2.15M |
| J9144 |
Injection, daratumumab, 10 mg and hyaluronidase-fihj |
561 |
229 |
$2.12M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
35,662 |
24,547 |
$1.89M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
33,551 |
22,092 |
$1.81M |
| 99499 |
|
23,819 |
17,750 |
$1.75M |
| 74183 |
|
4,721 |
4,677 |
$1.74M |
| J9202 |
Goserelin acetate implant, per 3.6 mg |
2,242 |
2,004 |
$1.73M |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
275,328 |
219,700 |
$1.69M |
| 77387 |
|
4,186 |
582 |
$1.62M |
| Q5118 |
Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg |
1,058 |
434 |
$1.57M |
| 0760 |
|
42,103 |
36,122 |
$1.48M |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
54,629 |
49,321 |
$1.46M |
| J9310 |
Injection, rituximab, 100 mg |
415 |
195 |
$1.43M |
| 72197 |
|
3,696 |
3,661 |
$1.40M |
| J9022 |
Injection, atezolizumab, 10 mg |
324 |
155 |
$1.38M |
| 77301 |
|
1,537 |
1,496 |
$1.38M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
22,738 |
18,380 |
$1.33M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
18,395 |
13,312 |
$1.28M |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
592 |
444 |
$1.24M |
| 0360 |
|
7,671 |
4,365 |
$1.19M |
| 77412 |
|
15,816 |
1,801 |
$1.09M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,877 |
5,314 |
$1.07M |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
4,716 |
4,637 |
$1.06M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
7,180 |
6,494 |
$1.05M |
| 70450 |
Computed tomography, head or brain; without contrast material |
8,381 |
7,909 |
$1.04M |
| 99199 |
Unlisted special service, procedure or report |
22,484 |
19,146 |
$1.03M |
| 87536 |
|
17,768 |
16,947 |
$1.03M |
| 0762 |
|
1,081 |
998 |
$1.01M |
| 71250 |
|
7,379 |
7,293 |
$983K |
| Q5103 |
Injection, infliximab-dyyb, biosimilar, (inflectra), 10 mg |
476 |
429 |
$983K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
26,713 |
20,818 |
$937K |
| J9316 |
Injection, pertuzumab, trastuzumab, and hyaluronidase-zzxf, per 10 mg |
196 |
95 |
$901K |
| Q5119 |
Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg |
441 |
202 |
$881K |
| Q3014 |
Telehealth originating site facility fee |
43,093 |
38,746 |
$856K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
6,794 |
6,563 |
$839K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
11,817 |
7,189 |
$813K |
| 97139 |
|
28,868 |
9,703 |
$785K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
22,258 |
20,527 |
$757K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
22,262 |
20,528 |
$752K |
| 93970 |
|
4,213 |
4,134 |
$736K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
11,539 |
10,047 |
$694K |
| 77066 |
Tomosynthesis, mammo |
5,963 |
5,870 |
$686K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
29,744 |
12,348 |
$674K |
| J1453 |
Injection, fosaprepitant, 1 mg |
7,687 |
3,234 |
$671K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
19,501 |
14,464 |
$667K |
| 77334 |
|
2,930 |
2,616 |
$659K |
| 77049 |
|
1,485 |
1,465 |
$639K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
3,668 |
3,516 |
$628K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
2,035 |
1,520 |
$622K |
| 97750 |
|
12,058 |
6,482 |
$619K |
| 87507 |
|
1,884 |
1,822 |
$612K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,645 |
2,609 |
$591K |
| J0585 |
Injection, onabotulinumtoxina, 1 unit |
1,342 |
576 |
$584K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
5,960 |
5,860 |
$577K |
| 76811 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed |
5,399 |
5,326 |
$575K |
| 86480 |
|
15,734 |
15,246 |
$560K |
| 77300 |
|
2,781 |
2,625 |
$547K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
13,424 |
12,532 |
$518K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
8,397 |
7,620 |
$517K |
| 77336 |
|
8,190 |
3,894 |
$516K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
2,330 |
2,290 |
$513K |
| 76830 |
Ultrasound, transvaginal |
5,781 |
5,679 |
$500K |
| 70486 |
|
2,771 |
2,725 |
$496K |
| 74178 |
|
1,985 |
1,967 |
$496K |
| 84443 |
Thyroid stimulating hormone (TSH) |
44,267 |
41,664 |
$487K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
10,302 |
9,486 |
$487K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,459 |
2,388 |
$485K |
| 71046 |
Radiologic examination, chest; 2 views |
18,754 |
17,506 |
$466K |
| 59025 |
Fetal non-stress test |
14,783 |
8,929 |
$459K |
| J2353 |
Injection, octreotide, depot form for intramuscular injection, 1 mg |
136 |
125 |
$449K |
| 86360 |
|
14,268 |
13,707 |
$448K |
| 72141 |
|
1,837 |
1,826 |
$446K |
| 93975 |
|
2,526 |
2,490 |
$446K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
7,370 |
5,780 |
$437K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
7,627 |
4,655 |
$433K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
5,208 |
5,120 |
$432K |
| 87497 |
|
10,426 |
6,653 |
$420K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
3,447 |
3,352 |
$417K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
4,557 |
4,535 |
$413K |
| 96417 |
|
8,135 |
5,446 |
$411K |
| 70491 |
|
2,264 |
2,231 |
$400K |
| 96415 |
|
9,016 |
7,001 |
$394K |
| 81220 |
CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants |
2,790 |
2,737 |
$392K |
| 77295 |
|
836 |
760 |
$389K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
1,430 |
1,417 |
$387K |
| J9395 |
Injection, fulvestrant, 25 mg |
559 |
478 |
$386K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
2,243 |
263 |
$372K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,394 |
1,360 |
$370K |
| 76642 |
|
5,620 |
5,199 |
$364K |
| G0422 |
Intensive cardiac rehabilitation; with or without continuous ecg monitoring with exercise, per session |
4,542 |
803 |
$362K |
| A9585 |
Injection, gadobutrol, 0.1 ml |
17,887 |
15,723 |
$359K |
| 77338 |
|
1,650 |
1,554 |
$357K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
46,295 |
30,767 |
$356K |
| 97597 |
|
8,433 |
4,964 |
$350K |
| 76801 |
|
5,090 |
4,877 |
$346K |
| 96367 |
|
7,670 |
5,203 |
$345K |
| 72156 |
|
658 |
651 |
$341K |
| 83735 |
|
50,291 |
32,456 |
$335K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,147 |
1,126 |
$334K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
18,399 |
18,049 |
$330K |
| J9358 |
Injection, fam-trastuzumab deruxtecan-nxki, 1 mg |
124 |
32 |
$329K |
| 0250 |
|
19,437 |
11,890 |
$326K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
1,199 |
1,167 |
$323K |
| 88185 |
|
1,711 |
1,529 |
$320K |
| J9173 |
Injection, durvalumab, 10 mg |
55 |
36 |
$309K |
| 76770 |
|
4,461 |
4,373 |
$306K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
16,443 |
15,923 |
$299K |
| 97799 |
|
12,352 |
3,261 |
$299K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
2,985 |
2,830 |
$293K |
| 76813 |
|
4,146 |
3,966 |
$289K |
| 93351 |
|
1,661 |
1,632 |
$288K |
| J9217 |
Leuprolide acetate (for depot suspension), 7.5 mg |
703 |
676 |
$288K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
3,849 |
3,782 |
$283K |
| 80197 |
|
22,617 |
11,873 |
$281K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
3,860 |
3,531 |
$280K |
| 93325 |
|
2,345 |
2,277 |
$274K |
| 86832 |
|
7,045 |
6,302 |
$273K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
6,786 |
5,429 |
$269K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
7,060 |
4,817 |
$268K |
| 94729 |
|
6,662 |
6,604 |
$265K |
| 95913 |
|
901 |
894 |
$259K |
| 86833 |
|
6,812 |
6,133 |
$259K |
| 94726 |
|
5,753 |
5,482 |
$255K |
| 86803 |
|
20,557 |
19,999 |
$252K |
| 81001 |
|
73,497 |
66,018 |
$243K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
37,838 |
37,089 |
$242K |
| 80061 |
Lipid panel |
30,741 |
30,160 |
$240K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
4,327 |
4,195 |
$239K |
| 82728 |
|
20,522 |
19,373 |
$239K |
| 99234 |
|
8,705 |
7,426 |
$237K |
| 88341 |
|
2,237 |
1,956 |
$235K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
34,310 |
31,397 |
$232K |
| G0423 |
Intensive cardiac rehabilitation; with or without continuous ecg monitoring; without exercise, per session |
2,883 |
586 |
$229K |
| 71045 |
Radiologic examination, chest; single view |
14,960 |
13,929 |
$215K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
32,928 |
29,004 |
$215K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
4,066 |
1,811 |
$214K |
| 78306 |
|
1,563 |
1,545 |
$214K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
2,346 |
2,295 |
$212K |
| 93971 |
|
2,295 |
2,241 |
$211K |
| 96416 |
|
2,871 |
1,666 |
$203K |
| 90715 |
|
4,953 |
4,876 |
$203K |
| 0710 |
|
6,686 |
6,364 |
$203K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
3,035 |
2,261 |
$198K |
| 77290 |
|
1,225 |
1,067 |
$193K |
| 72158 |
|
424 |
420 |
$191K |
| 77065 |
Tomosynthesis, mammo |
2,177 |
2,114 |
$189K |
| 83880 |
|
10,094 |
9,277 |
$189K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
3,122 |
2,888 |
$188K |
| 77062 |
|
4,427 |
4,380 |
$188K |
| Z7502 |
|
5,042 |
4,980 |
$188K |
| J9070 |
Cyclophosphamide, 100 mg |
701 |
283 |
$187K |
| 76536 |
|
2,774 |
2,746 |
$184K |
| 90651 |
|
706 |
690 |
$183K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
1,650 |
1,622 |
$182K |
| 90677 |
|
770 |
767 |
$180K |
| 72131 |
|
1,201 |
1,186 |
$176K |
| 86900 |
|
26,129 |
21,173 |
$175K |
| 90750 |
|
1,242 |
1,194 |
$172K |
| 70543 |
|
440 |
438 |
$171K |
| 0270 |
|
19,401 |
10,678 |
$170K |
| 81329 |
|
2,385 |
2,347 |
$170K |
| 73610 |
|
5,100 |
4,826 |
$170K |
| 77373 |
|
183 |
51 |
$169K |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
144 |
124 |
$169K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
5,307 |
5,237 |
$168K |
| 70496 |
|
847 |
835 |
$167K |
| 72157 |
|
279 |
276 |
$166K |
| 93880 |
|
1,575 |
1,558 |
$166K |
| Q5114 |
Injection, trastuzumab-dkst, biosimilar, (ogivri), 10 mg |
88 |
58 |
$165K |
| 93458 |
|
197 |
192 |
$164K |
| 99152 |
|
3,819 |
3,640 |
$164K |
| 86003 |
|
2,297 |
1,914 |
$163K |
| 96402 |
|
5,370 |
4,819 |
$162K |
| 73630 |
|
5,462 |
5,218 |
$161K |
| 0370 |
|
2,786 |
2,516 |
$160K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
1,231 |
1,203 |
$158K |
| 72100 |
|
6,079 |
5,940 |
$158K |
| 92557 |
|
2,402 |
2,366 |
$155K |
| 83970 |
|
6,888 |
6,680 |
$153K |
| 84484 |
|
14,797 |
11,200 |
$150K |
| 73130 |
|
4,345 |
4,077 |
$150K |
| 95886 |
|
2,578 |
2,526 |
$148K |
| 86780 |
|
17,158 |
16,720 |
$147K |
| 94010 |
|
7,041 |
6,774 |
$147K |
| 73110 |
|
4,188 |
3,859 |
$146K |
| 73221 |
|
383 |
374 |
$146K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
124 |
54 |
$146K |
| 97598 |
|
885 |
571 |
$146K |
| 73502 |
|
5,227 |
5,022 |
$145K |
| 86850 |
|
24,417 |
19,696 |
$145K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
468 |
457 |
$145K |
| 82107 |
|
4,683 |
4,364 |
$142K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
6,707 |
3,474 |
$141K |
| Z7500 |
|
4,409 |
4,023 |
$141K |
| 82784 |
|
12,135 |
8,561 |
$140K |
| 99215 |
Prolong outpt/office vis |
2,382 |
1,910 |
$140K |
| 97802 |
|
2,179 |
2,165 |
$138K |
| 90686 |
|
6,500 |
6,275 |
$137K |
| 87522 |
Neg quan hep c or qual rna |
4,442 |
4,126 |
$137K |
| 87340 |
|
13,615 |
13,275 |
$135K |
| J0185 |
Injection, aprepitant, 1 mg |
1,063 |
452 |
$134K |
| J2785 |
Injection, regadenoson, 0.1 mg |
967 |
949 |
$131K |
| 90734 |
|
1,151 |
1,103 |
$131K |
| 93320 |
|
1,406 |
1,392 |
$129K |
| 87799 |
|
4,342 |
3,240 |
$128K |
| 70498 |
|
680 |
670 |
$128K |
| 96523 |
|
2,114 |
1,708 |
$127K |
| 84439 |
|
17,681 |
15,884 |
$125K |
| 82378 |
|
8,822 |
7,770 |
$125K |
| 73030 |
|
4,542 |
4,354 |
$124K |
| 73562 |
|
4,009 |
3,854 |
$118K |
| 82607 |
|
12,007 |
11,737 |
$117K |
| 74246 |
|
1,062 |
1,043 |
$117K |
| 99221 |
|
2,662 |
2,287 |
$115K |
| 84100 |
|
36,271 |
25,221 |
$115K |
| 83951 |
|
3,544 |
3,265 |
$115K |
| 85610 |
|
32,952 |
29,099 |
$113K |
| J9354 |
Injection, ado-trastuzumab emtansine, 1 mg |
38 |
13 |
$112K |
| 94060 |
|
2,581 |
2,553 |
$112K |
| 77080 |
|
2,560 |
2,542 |
$109K |
| 83550 |
|
16,149 |
15,549 |
$108K |
| 76942 |
|
2,487 |
2,321 |
$108K |
| 83615 |
|
27,615 |
16,058 |
$107K |
| 88342 |
|
3,535 |
3,341 |
$106K |
| J2704 |
Injection, propofol, 10 mg |
15,194 |
8,009 |
$106K |
| 87088 |
|
18,290 |
17,253 |
$105K |
| G0378 |
Hospital observation service, per hour |
2,501 |
1,870 |
$103K |
| 83540 |
|
17,559 |
16,860 |
$102K |
| 84403 |
|
6,432 |
6,206 |
$102K |
| 82570 |
|
23,853 |
20,967 |
$102K |
| 91010 |
|
1,995 |
1,966 |
$101K |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
1,165 |
1,138 |
$101K |
| 86235 |
|
2,499 |
2,113 |
$101K |
| 82533 |
|
7,716 |
6,539 |
$100K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
4,458 |
4,434 |
$99K |
| 85027 |
|
20,316 |
18,271 |
$98K |
| 86901 |
|
25,722 |
20,951 |
$98K |
| 87077 |
|
17,126 |
15,530 |
$97K |
| 82248 |
|
23,635 |
13,280 |
$96K |
| 36415 |
Collection of venous blood by venipuncture |
38,511 |
31,805 |
$95K |
| 88112 |
|
3,012 |
2,896 |
$95K |
| 73560 |
|
4,244 |
4,031 |
$93K |
| J9045 |
Injection, carboplatin, 50 mg |
2,478 |
1,652 |
$93K |
| 87480 |
|
5,581 |
5,329 |
$92K |
| 84153 |
|
7,601 |
7,258 |
$92K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
1,227 |
1,104 |
$92K |
| 90732 |
|
920 |
880 |
$92K |
| 87186 |
|
13,864 |
12,626 |
$91K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,273 |
1,153 |
$91K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
2,868 |
1,552 |
$91K |
| 86923 |
|
1,671 |
1,306 |
$90K |
| 97165 |
|
1,692 |
1,578 |
$90K |
| 87510 |
|
5,513 |
5,265 |
$90K |
| 84702 |
|
6,043 |
4,944 |
$90K |
| J9267 |
Injection, paclitaxel, 1 mg |
4,464 |
1,237 |
$89K |
| 93925 |
|
1,233 |
1,217 |
$88K |
| 90670 |
|
473 |
453 |
$88K |
| 78264 |
|
294 |
288 |
$88K |
| 72040 |
|
2,986 |
2,892 |
$87K |
| 97163 |
|
1,672 |
862 |
$87K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,733 |
1,555 |
$86K |
| 86160 |
|
4,990 |
4,156 |
$86K |
| 91037 |
|
1,680 |
1,653 |
$86K |
| 86706 |
|
8,089 |
7,912 |
$85K |
| 88307 |
|
1,369 |
1,262 |
$85K |
| 81513 |
|
1,451 |
1,424 |
$84K |
| 83690 |
|
13,621 |
12,061 |
$84K |
| 87660 |
|
5,577 |
5,326 |
$84K |
| 74174 |
|
315 |
312 |
$83K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
65 |
65 |
$83K |
| 96376 |
|
4,094 |
2,738 |
$82K |
| 97161 |
|
2,267 |
2,189 |
$81K |
| 77059 |
|
133 |
132 |
$80K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
1,303 |
1,188 |
$79K |
| 87653 |
|
3,701 |
3,617 |
$78K |
| Z9725 |
|
2,576 |
2,483 |
$77K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
16,119 |
11,736 |
$77K |
| 86704 |
|
6,462 |
6,332 |
$77K |
| 97803 |
|
2,220 |
2,063 |
$76K |
| 86140 |
|
19,448 |
18,209 |
$75K |
| 85730 |
|
14,828 |
13,693 |
$74K |
| 88142 |
|
7,875 |
7,749 |
$74K |
| 87517 |
|
2,614 |
2,515 |
$74K |
| 97166 |
|
1,680 |
1,072 |
$74K |
| 96411 |
|
2,634 |
1,790 |
$73K |
| J9171 |
Injection, docetaxel, 1 mg |
649 |
296 |
$73K |
| 82746 |
|
6,312 |
6,139 |
$73K |
| 82670 |
|
3,089 |
2,980 |
$72K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
2,725 |
2,382 |
$72K |
| 80076 |
|
10,628 |
9,986 |
$72K |
| 88184 |
|
1,680 |
1,602 |
$71K |
| 93976 |
|
510 |
505 |
$71K |
| 20610 |
|
2,924 |
2,491 |
$71K |
| 72050 |
|
1,191 |
1,176 |
$70K |
| 86300 |
|
5,440 |
4,613 |
$70K |
| 93017 |
|
1,455 |
1,422 |
$69K |
| 94621 |
|
646 |
636 |
$69K |
| J9206 |
Injection, irinotecan, 20 mg |
1,703 |
555 |
$68K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
376 |
371 |
$67K |
| 93356 |
|
1,761 |
1,754 |
$64K |
| 86334 |
|
4,389 |
4,063 |
$64K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,232 |
1,142 |
$63K |
| 72082 |
|
1,401 |
1,368 |
$63K |
| A9581 |
Injection, gadoxetate disodium, 1 ml |
764 |
762 |
$62K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
10,391 |
9,986 |
$62K |
| 73700 |
|
385 |
384 |
$62K |
| 84156 |
|
19,540 |
16,654 |
$62K |
| 70480 |
|
271 |
267 |
$61K |
| 83883 |
|
5,861 |
3,784 |
$59K |
| J3489 |
Injection, zoledronic acid, 1 mg |
1,441 |
1,392 |
$59K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
979 |
906 |
$59K |
| 93296 |
|
2,325 |
2,277 |
$58K |
| 99497 |
|
1,026 |
994 |
$57K |
| 81335 |
|
676 |
668 |
$57K |
| 83021 |
|
4,682 |
4,450 |
$57K |
| 86787 |
|
5,475 |
5,262 |
$56K |
| 72110 |
|
1,125 |
1,113 |
$56K |
| 87481 |
|
1,967 |
1,560 |
$56K |
| 73590 |
|
2,192 |
2,097 |
$55K |
| J2796 |
Injection, romiplostim, 10 micrograms |
43 |
12 |
$53K |
| 76870 |
|
884 |
872 |
$53K |
| 73120 |
|
1,090 |
1,032 |
$52K |
| 99205 |
Prolong outpt/office vis |
614 |
534 |
$52K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
1,460 |
1,436 |
$52K |
| 96377 |
|
1,574 |
1,148 |
$51K |
| 96401 |
|
2,096 |
1,284 |
$50K |
| 72070 |
|
1,968 |
1,902 |
$50K |
| A9520 |
Technetium tc-99m tilmanocept, diagnostic, up to 0.5 millicuries |
154 |
149 |
$50K |
| 85652 |
|
19,050 |
18,076 |
$48K |
| 81408 |
|
274 |
270 |
$48K |
| 86762 |
|
4,390 |
4,272 |
$47K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
7,189 |
4,550 |
$47K |
| 86038 |
|
4,189 |
4,124 |
$46K |
| 86225 |
|
3,836 |
3,753 |
$46K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
11,027 |
4,919 |
$46K |
| 87040 |
|
3,680 |
2,892 |
$46K |
| 82962 |
|
10,483 |
8,749 |
$46K |
| 62323 |
|
304 |
295 |
$46K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
345 |
338 |
$46K |
| 96409 |
|
1,756 |
990 |
$45K |
| 96368 |
|
2,118 |
1,396 |
$45K |
| 70544 |
|
203 |
200 |
$45K |
| 82550 |
|
8,827 |
6,928 |
$45K |
| 99070 |
|
7,302 |
2,439 |
$45K |
| 90746 |
|
668 |
643 |
$44K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
2,653 |
471 |
$44K |
| 74018 |
|
2,322 |
2,168 |
$44K |
| 81025 |
|
7,432 |
6,831 |
$44K |
| 72146 |
|
180 |
180 |
$43K |
| 74221 |
|
529 |
526 |
$43K |
| 84270 |
|
3,432 |
3,319 |
$43K |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
929 |
929 |
$42K |
| J0741 |
Injection, cabotegravir and rilpivirine, 2mg/3mg |
150 |
125 |
$42K |
| 78195 |
|
214 |
212 |
$42K |
| 93922 |
|
1,261 |
1,252 |
$42K |
| 93505 |
|
33 |
25 |
$42K |
| 84165 |
|
5,377 |
5,028 |
$41K |
| 86902 |
|
849 |
708 |
$40K |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
399 |
381 |
$40K |
| 73080 |
|
1,036 |
1,007 |
$40K |
| 83605 |
|
4,230 |
3,660 |
$39K |
| 99153 |
Mod sedat endo service >5yrs |
2,112 |
2,035 |
$39K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
990 |
973 |
$39K |
| 92567 |
|
1,437 |
1,416 |
$39K |
| J9190 |
Injection, fluorouracil, 500 mg |
2,172 |
990 |
$39K |
| 87070 |
|
6,647 |
5,952 |
$39K |
| 95912 |
|
272 |
265 |
$38K |
| 91065 |
|
1,374 |
1,279 |
$38K |
| 86304 |
|
3,241 |
2,794 |
$38K |
| 82977 |
|
5,964 |
2,792 |
$37K |
| 0700 |
|
630 |
506 |
$37K |
| 73552 |
|
1,648 |
1,585 |
$37K |
| 82553 |
|
4,270 |
2,828 |
$36K |
| 86301 |
|
2,737 |
2,370 |
$36K |
| 83001 |
|
2,431 |
2,383 |
$36K |
| 82805 |
|
1,147 |
1,067 |
$36K |
| 77470 |
|
347 |
342 |
$36K |
| 99417 |
Prolong home eval add 15m |
1,055 |
1,031 |
$35K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
2,073 |
1,593 |
$35K |
| 76820 |
|
962 |
734 |
$34K |
| 86708 |
|
2,784 |
2,739 |
$34K |
| 73564 |
|
888 |
878 |
$34K |
| 75574 |
|
200 |
199 |
$34K |
| 86355 |
|
1,490 |
1,402 |
$33K |
| 94618 |
|
1,357 |
1,238 |
$33K |
| 72170 |
|
1,319 |
1,273 |
$32K |
| 83516 |
|
3,134 |
2,785 |
$32K |
| 82105 |
|
2,254 |
2,104 |
$32K |
| 81283 |
|
471 |
466 |
$31K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
15,097 |
12,882 |
$31K |
| 97010 |
|
735 |
359 |
$31K |
| 84550 |
|
9,838 |
8,451 |
$30K |
| 74160 |
|
125 |
124 |
$30K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
13,725 |
10,437 |
$30K |
| 31231 |
|
1,286 |
1,256 |
$29K |
| 86255 |
|
2,456 |
2,358 |
$29K |
| 91200 |
|
566 |
557 |
$29K |
| 80195 |
|
3,717 |
2,589 |
$29K |
| 52000 |
|
494 |
483 |
$29K |
| 77061 |
|
762 |
751 |
$28K |
| 84146 |
|
1,731 |
1,689 |
$28K |
| 31575 |
|
569 |
539 |
$28K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
13,517 |
12,783 |
$28K |
| 92610 |
|
887 |
866 |
$28K |
| 0942 |
|
416 |
375 |
$28K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
5,856 |
5,237 |
$27K |
| L4360 |
Walking boot, pneumatic and/or vacuum, with or without joints, with or without interface material, prefabricated item that has been trimmed, bent, molded, assembled, or otherwise customized to fit a specific patient by an individual with expertise |
122 |
116 |
$27K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
3,281 |
3,103 |
$27K |
| 84480 |
|
2,557 |
2,452 |
$27K |
| 86769 |
|
802 |
758 |
$27K |
| 0761 |
|
870 |
764 |
$26K |
| 36430 |
|
328 |
218 |
$26K |
| 86147 |
|
1,155 |
830 |
$26K |
| 86665 |
|
864 |
755 |
$26K |
| 73090 |
|
1,010 |
967 |
$25K |
| 82951 |
|
2,206 |
2,183 |
$25K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
6,737 |
5,954 |
$25K |
| Q5108 |
Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg |
13 |
12 |
$25K |
| 86593 |
|
6,826 |
6,497 |
$24K |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
1,467 |
1,451 |
$24K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
289 |
258 |
$24K |
| 80158 |
|
2,170 |
1,306 |
$24K |
| 77332 |
|
646 |
615 |
$24K |
| 81406 |
|
712 |
706 |
$24K |
| J9201 |
Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg |
761 |
343 |
$24K |
| 86039 |
|
2,307 |
2,241 |
$23K |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
244 |
147 |
$23K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
4,501 |
1,875 |
$23K |
| 77417 |
|
779 |
373 |
$23K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
1,405 |
888 |
$23K |
| 85379 |
|
2,519 |
2,365 |
$23K |
| 0914 |
|
823 |
762 |
$23K |
| 43235 |
|
230 |
217 |
$22K |
| 82785 |
|
2,076 |
2,045 |
$22K |
| 86870 |
|
779 |
686 |
$22K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
8,978 |
6,803 |
$22K |
| 77280 |
|
326 |
292 |
$22K |
| 97116 |
|
879 |
577 |
$21K |
| 83520 |
|
2,130 |
2,040 |
$21K |
| J1644 |
Injection, heparin sodium, per 1000 units |
3,718 |
2,096 |
$21K |
| 82043 |
|
6,167 |
6,053 |
$21K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
3,865 |
3,259 |
$21K |
| 43259 |
|
204 |
202 |
$21K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
3,235 |
2,543 |
$21K |
| 87116 |
|
3,262 |
2,596 |
$21K |
| 82610 |
|
3,093 |
3,001 |
$21K |
| 86705 |
|
1,686 |
1,663 |
$21K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,285 |
960 |
$20K |
| 87081 |
|
4,163 |
4,021 |
$20K |
| 0521 |
|
597 |
461 |
$20K |
| 81370 |
|
41 |
41 |
$20K |
| 82565 |
|
5,196 |
4,992 |
$20K |
| 86644 |
|
1,598 |
1,461 |
$19K |
| 71271 |
|
204 |
204 |
$19K |
| J1756 |
Injection, iron sucrose, 1 mg |
685 |
111 |
$19K |
| 87486 |
|
776 |
760 |
$19K |
| 87015 |
|
3,997 |
3,022 |
$18K |
| 86825 |
|
149 |
147 |
$18K |
| 87581 |
|
761 |
747 |
$18K |
| J2560 |
Injection, phenobarbital sodium, up to 120 mg |
349 |
259 |
$17K |
| 87102 |
|
2,719 |
2,493 |
$17K |
| 78816 |
|
12 |
12 |
$17K |
| J0485 |
Injection, belatacept, 1 mg |
59 |
29 |
$17K |
| J9060 |
Injection, cisplatin, powder or solution, 10 mg |
893 |
382 |
$17K |
| 88313 |
|
712 |
635 |
$17K |
| 81226 |
|
605 |
601 |
$17K |
| 83002 |
|
1,101 |
1,085 |
$17K |
| 93299 |
|
379 |
374 |
$17K |
| 76391 |
|
68 |
67 |
$16K |
| 81401 |
|
876 |
868 |
$16K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
2,520 |
2,221 |
$16K |
| 73060 |
|
717 |
674 |
$16K |
| 88304 |
|
917 |
869 |
$16K |
| 87493 |
|
1,209 |
1,177 |
$16K |
| 82150 |
|
3,405 |
2,569 |
$16K |
| 27500 |
|
74 |
63 |
$16K |
| 77073 |
|
757 |
739 |
$15K |
| 86146 |
|
554 |
471 |
$15K |
| 86356 |
|
244 |
225 |
$15K |
| 87205 |
|
5,606 |
5,017 |
$15K |
| 90662 |
|
697 |
679 |
$15K |
| V2632 |
Posterior chamber intraocular lens |
181 |
156 |
$15K |
| 86431 |
|
2,455 |
2,396 |
$15K |
| 49083 |
|
386 |
263 |
$14K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
418 |
378 |
$14K |
| 87338 |
|
1,506 |
1,489 |
$14K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
98 |
93 |
$14K |
| 85045 |
|
4,159 |
3,648 |
$14K |
| 80069 |
|
2,318 |
2,222 |
$14K |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
1,064 |
1,057 |
$14K |
| 72128 |
|
95 |
95 |
$14K |
| 76825 |
|
114 |
107 |
$13K |
| 81206 |
|
255 |
240 |
$13K |
| 92004 |
Ophthalmological services: medical examination and evaluation, comprehensive, new patient |
288 |
284 |
$13K |
| 82803 |
|
1,120 |
992 |
$13K |
| 76882 |
|
270 |
268 |
$13K |
| 90636 |
|
129 |
122 |
$13K |
| 86635 |
|
1,474 |
1,390 |
$13K |
| 73620 |
|
193 |
187 |
$13K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
2,830 |
2,466 |
$12K |
| 87206 |
|
3,243 |
2,536 |
$12K |
| 91320 |
|
167 |
167 |
$12K |
| 95911 |
|
104 |
104 |
$11K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
570 |
561 |
$11K |
| 86200 |
|
1,647 |
1,613 |
$11K |
| 94799 |
|
525 |
510 |
$11K |
| 0681 |
|
29 |
27 |
$11K |
| 81225 |
|
605 |
601 |
$11K |
| 92012 |
Ophthalmological services: medical examination and evaluation, intermediate, established patient |
340 |
299 |
$11K |
| 82950 |
|
2,608 |
2,593 |
$11K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
177 |
173 |
$11K |
| 86141 |
|
1,147 |
1,111 |
$11K |
| 92611 |
|
374 |
371 |
$11K |
| J0881 |
Injection, darbepoetin alfa, 1 microgram (non-esrd use) |
36 |
13 |
$11K |
| 81455 |
|
12 |
12 |
$10K |
| Q0138 |
Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) |
265 |
44 |
$10K |
| 82310 |
|
1,653 |
1,492 |
$10K |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
2,039 |
1,164 |
$10K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
1,160 |
571 |
$10K |
| 93926 |
|
168 |
166 |
$10K |
| 73140 |
|
559 |
532 |
$10K |
| 82103 |
|
1,323 |
1,223 |
$10K |
| 88271 |
|
435 |
384 |
$10K |
| 73070 |
|
370 |
348 |
$10K |
| 46600 |
|
838 |
833 |
$9K |
| 76881 |
|
108 |
100 |
$9K |
| 87075 |
|
1,391 |
1,309 |
$9K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
38 |
24 |
$9K |
| 64615 |
|
277 |
271 |
$9K |
| 73720 |
|
25 |
25 |
$9K |
| 85613 |
|
683 |
633 |
$9K |
| 96111 |
|
85 |
85 |
$9K |
| 83993 |
|
779 |
774 |
$9K |
| 92612 |
|
79 |
75 |
$8K |
| 86645 |
|
494 |
482 |
$8K |
| 86800 |
|
1,430 |
1,386 |
$8K |
| 84134 |
|
892 |
857 |
$8K |
| 86703 |
|
675 |
653 |
$8K |
| 92550 |
|
467 |
463 |
$8K |
| 90739 |
|
157 |
156 |
$8K |
| 81405 |
|
205 |
202 |
$8K |
| 36561 |
|
93 |
93 |
$8K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
904 |
789 |
$8K |
| 92014 |
Ophthalmological services: medical examination and evaluation, comprehensive, established patient |
278 |
272 |
$8K |
| 84432 |
|
977 |
943 |
$8K |
| 84425 |
|
1,513 |
1,492 |
$8K |
| 82232 |
|
858 |
832 |
$8K |
| 36416 |
|
1,998 |
1,606 |
$8K |
| 86835 |
|
85 |
79 |
$7K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
226 |
114 |
$7K |
| 81230 |
|
610 |
606 |
$7K |
| 99231 |
Subsequent hospital care, per day, straightforward or low complexity |
125 |
115 |
$7K |
| 90632 |
|
115 |
113 |
$7K |
| 81231 |
|
612 |
606 |
$7K |
| 94664 |
|
747 |
715 |
$7K |
| 82330 |
|
815 |
671 |
$7K |
| 81328 |
|
514 |
510 |
$7K |
| 81232 |
|
517 |
513 |
$7K |
| 77091 |
|
362 |
360 |
$7K |
| 73200 |
|
38 |
37 |
$7K |
| 81227 |
|
604 |
600 |
$6K |
| 82274 |
|
1,119 |
1,098 |
$6K |
| 86828 |
|
111 |
110 |
$6K |
| 86945 |
|
207 |
115 |
$6K |
| 82390 |
|
568 |
562 |
$6K |
| 84460 |
|
1,465 |
1,361 |
$6K |
| 78830 |
|
26 |
24 |
$6K |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
203 |
195 |
$6K |
| 87529 |
|
185 |
142 |
$6K |
| 85660 |
|
618 |
472 |
$6K |
| 74170 |
|
13 |
12 |
$6K |
| 76827 |
|
74 |
73 |
$6K |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
305 |
178 |
$6K |
| 86765 |
|
654 |
614 |
$6K |
| 90656 |
|
329 |
329 |
$6K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
101 |
94 |
$6K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
1,249 |
797 |
$6K |
| 20553 |
|
460 |
425 |
$6K |
| 84450 |
|
1,357 |
1,255 |
$6K |
| 51700 |
|
336 |
109 |
$6K |
| 82947 |
|
1,940 |
1,820 |
$6K |
| 88346 |
|
143 |
126 |
$6K |
| C1781 |
Mesh (implantable) |
13 |
13 |
$5K |
| 97162 |
|
99 |
97 |
$5K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
33 |
25 |
$5K |
| J1071 |
Injection, testosterone cypionate, 1 mg |
1,363 |
435 |
$5K |
| 87631 |
|
87 |
83 |
$5K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
581 |
313 |
$5K |
| 29705 |
|
486 |
454 |
$5K |
| 80164 |
|
467 |
428 |
$5K |
| 75561 |
|
28 |
28 |
$5K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,200 |
1,075 |
$5K |
| 83010 |
|
644 |
567 |
$5K |
| G0008 |
Administration of influenza virus vaccine |
938 |
891 |
$5K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
1,311 |
1,257 |
$5K |
| 76376 |
|
114 |
110 |
$5K |
| 90480 |
|
409 |
408 |
$4K |
| 85384 |
|
569 |
416 |
$4K |
| 86790 |
|
501 |
469 |
$4K |
| 84520 |
|
1,492 |
1,329 |
$4K |
| 84436 |
|
590 |
577 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
894 |
783 |
$4K |
| 93226 |
|
89 |
87 |
$4K |
| 88312 |
|
299 |
281 |
$4K |
| J1815 |
Injection, insulin, per 5 units |
1,473 |
720 |
$4K |
| 81376 |
|
58 |
54 |
$4K |
| 86880 |
|
534 |
417 |
$4K |
| 0272 |
|
675 |
592 |
$4K |
| 80187 |
|
264 |
203 |
$4K |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
1,069 |
1,050 |
$4K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
424 |
352 |
$4K |
| 86777 |
|
319 |
313 |
$4K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
200 |
184 |
$4K |
| 90694 |
|
244 |
243 |
$4K |
| 16020 |
|
79 |
71 |
$4K |
| 0301 |
|
120 |
106 |
$4K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
376 |
367 |
$4K |
| 82104 |
|
609 |
601 |
$4K |
| 72190 |
|
57 |
56 |
$4K |
| 81003 |
|
2,093 |
1,824 |
$4K |
| 95887 |
|
72 |
50 |
$4K |
| 93319 |
|
48 |
48 |
$4K |
| 86709 |
|
347 |
339 |
$4K |
| 92526 |
|
219 |
192 |
$4K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
13 |
13 |
$4K |
| 83695 |
|
570 |
560 |
$3K |
| 71020 |
|
138 |
54 |
$3K |
| 87305 |
|
569 |
404 |
$3K |
| 62321 |
|
13 |
13 |
$3K |
| L3260 |
Surgical boot/shoe, each |
112 |
104 |
$3K |
| 73521 |
|
100 |
95 |
$3K |
| 81268 |
|
20 |
15 |
$3K |
| 86376 |
|
287 |
282 |
$3K |
| 94625 |
|
132 |
53 |
$3K |
| 82024 |
|
335 |
322 |
$3K |
| 81355 |
|
502 |
498 |
$3K |
| 83921 |
|
461 |
459 |
$3K |
| 73000 |
|
131 |
122 |
$3K |
| 94727 |
|
124 |
124 |
$3K |
| 86778 |
|
233 |
230 |
$3K |
| 86677 |
|
277 |
273 |
$3K |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
709 |
221 |
$3K |
| 51798 |
|
254 |
237 |
$3K |
| Z7610 |
|
2,803 |
1,231 |
$3K |
| 81241 |
|
609 |
604 |
$3K |
| 99217 |
|
27 |
25 |
$3K |
| M0247 |
Intravenous infusion, sotrovimab, includes infusion and post administration monitoring |
28 |
28 |
$3K |
| 86256 |
|
279 |
270 |
$3K |
| 87899 |
|
535 |
465 |
$3K |
| 74182 |
|
13 |
13 |
$3K |
| J2060 |
Injection, lorazepam, 2 mg |
1,733 |
1,415 |
$3K |
| 84300 |
|
752 |
679 |
$3K |
| 81404 |
|
188 |
188 |
$3K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
784 |
702 |
$3K |
| 81240 |
|
612 |
607 |
$3K |
| 81291 |
|
611 |
605 |
$3K |
| 99429 |
|
181 |
177 |
$3K |
| 93798 |
|
120 |
24 |
$2K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
426 |
397 |
$2K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
109 |
103 |
$2K |
| 93750 |
|
63 |
53 |
$2K |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
780 |
592 |
$2K |
| 10060 |
|
88 |
79 |
$2K |
| A9609 |
Fludeoxyglucose f18 up to 15 millicuries |
63 |
63 |
$2K |
| 82525 |
|
356 |
354 |
$2K |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
291 |
288 |
$2K |
| 29581 |
|
114 |
61 |
$2K |
| J9075 |
Injection, cyclophosphamide, not otherwise specified, 5 mg |
43 |
14 |
$2K |
| 82140 |
|
195 |
184 |
$2K |
| J1940 |
Injection, furosemide, up to 20 mg |
424 |
352 |
$2K |
| J1626 |
Injection, granisetron hydrochloride, 100 mcg |
375 |
194 |
$2K |
| Q9968 |
Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg |
15 |
14 |
$2K |
| 88173 |
|
54 |
52 |
$2K |
| 81402 |
|
203 |
203 |
$2K |
| 81002 |
|
931 |
865 |
$2K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
577 |
542 |
$2K |
| 87999 |
|
21 |
21 |
$2K |
| 97014 |
|
92 |
52 |
$2K |
| C1769 |
Guide wire |
355 |
325 |
$2K |
| 86364 |
|
133 |
132 |
$2K |
| 87901 |
|
12 |
12 |
$2K |
| 76981 |
|
36 |
36 |
$2K |
| 84630 |
|
338 |
334 |
$2K |
| 36591 |
|
187 |
160 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
72 |
67 |
$2K |
| 93990 |
|
26 |
26 |
$2K |
| 82952 |
|
473 |
473 |
$2K |
| 84132 |
|
730 |
618 |
$2K |
| 95816 |
|
39 |
39 |
$2K |
| 87506 |
|
13 |
13 |
$2K |
| 74220 |
|
55 |
55 |
$2K |
| 92504 |
|
116 |
114 |
$2K |
| 90740 |
|
13 |
13 |
$2K |
| 82075 |
|
86 |
83 |
$2K |
| J3480 |
Injection, potassium chloride, per 2 meq |
1,452 |
568 |
$2K |
| 92015 |
Determination of refractive state |
170 |
168 |
$2K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
264 |
240 |
$2K |
| 84145 |
|
157 |
147 |
$2K |
| 95872 |
|
26 |
26 |
$2K |
| 86834 |
|
14 |
12 |
$2K |
| 86696 |
|
100 |
95 |
$2K |
| 97535 |
Self-care/home management training, each 15 minutes |
82 |
63 |
$1K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
32 |
28 |
$1K |
| 74230 |
|
52 |
50 |
$1K |
| 76999 |
|
33 |
33 |
$1K |
| A9577 |
Injection, gadobenate dimeglumine (multihance), per ml |
41 |
41 |
$1K |
| 87210 |
|
175 |
119 |
$1K |
| 84133 |
|
406 |
360 |
$1K |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
927 |
723 |
$1K |
| 92522 |
|
14 |
13 |
$1K |
| J1790 |
Injection, droperidol, up to 5 mg |
252 |
223 |
$1K |
| 93225 |
|
46 |
46 |
$1K |
| 86015 |
|
272 |
267 |
$1K |
| 82077 |
|
65 |
64 |
$1K |
| 87420 |
|
173 |
171 |
$1K |
| 82040 |
|
528 |
504 |
$1K |
| 82436 |
|
336 |
301 |
$1K |
| 84157 |
|
432 |
400 |
$1K |
| 86695 |
|
100 |
95 |
$1K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
274 |
257 |
$1K |
| 95910 |
|
14 |
14 |
$1K |
| 88237 |
|
31 |
27 |
$1K |
| 91322 |
|
94 |
93 |
$1K |
| 87806 |
|
51 |
50 |
$1K |
| 86922 |
|
36 |
25 |
$1K |
| 99245 |
|
12 |
12 |
$1K |
| 29125 |
|
26 |
24 |
$1K |
| 87900 |
|
13 |
13 |
$1K |
| 87181 |
|
957 |
872 |
$1K |
| 89051 |
|
396 |
362 |
$1K |
| 0064A |
|
46 |
46 |
$1K |
| 76937 |
|
57 |
56 |
$1K |
| 92134 |
|
42 |
41 |
$1K |
| 87906 |
|
12 |
12 |
$1K |
| 97755 |
|
42 |
42 |
$982.80 |
| 80177 |
|
165 |
165 |
$958.65 |
| 84238 |
|
120 |
119 |
$935.06 |
| J3370 |
Injection, vancomycin hcl, 500 mg |
92 |
61 |
$932.30 |
| 81400 |
|
197 |
197 |
$923.56 |
| 86753 |
|
126 |
120 |
$913.98 |
| 51784 |
|
41 |
41 |
$912.18 |
| 72080 |
|
31 |
30 |
$903.69 |
| J1250 |
Injection, dobutamine hydrochloride, per 250 mg |
115 |
113 |
$900.85 |
| 76821 |
|
17 |
12 |
$898.96 |
| 90674 |
|
53 |
53 |
$885.63 |
| 69210 |
|
82 |
82 |
$853.84 |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
41 |
29 |
$846.76 |
| 0390 |
|
58 |
51 |
$839.10 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
1,333 |
1,291 |
$821.66 |
| 87209 |
|
76 |
50 |
$807.69 |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
17 |
15 |
$803.82 |
| J1630 |
Injection, haloperidol, up to 5 mg |
267 |
213 |
$802.48 |
| 86735 |
|
92 |
83 |
$785.55 |
| 82810 |
|
79 |
65 |
$763.15 |
| 92083 |
|
67 |
66 |
$758.54 |
| 87252 |
|
33 |
29 |
$736.49 |
| 84144 |
|
38 |
38 |
$724.91 |
| C1726 |
Catheter, balloon dilatation, non-vascular |
26 |
26 |
$705.21 |
| 82747 |
|
68 |
68 |
$677.84 |
| 82239 |
|
77 |
69 |
$645.35 |
| 83090 |
|
63 |
63 |
$644.59 |
| 75571 |
|
14 |
14 |
$639.66 |
| 88311 |
|
166 |
158 |
$626.71 |
| 87385 |
|
70 |
66 |
$623.30 |
| X3920 |
|
12 |
12 |
$599.64 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
202 |
168 |
$596.07 |
| J2305 |
Injection, nitroglycerin, 5 mg |
88 |
58 |
$585.02 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
26 |
26 |
$576.35 |
| 51702 |
|
27 |
25 |
$563.89 |
| 20611 |
|
13 |
13 |
$553.20 |
| Q9965 |
Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml |
78 |
75 |
$538.81 |
| 84207 |
|
121 |
120 |
$532.82 |
| 0134A |
|
48 |
48 |
$524.13 |
| 90833 |
Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) |
250 |
202 |
$522.99 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
15 |
15 |
$517.80 |
| 87184 |
|
141 |
129 |
$506.35 |
| 84182 |
|
36 |
25 |
$499.47 |
| 0124A |
|
30 |
29 |
$489.76 |
| 81050 |
|
372 |
362 |
$477.03 |
| J9370 |
Vincristine sulfate, 1 mg |
34 |
25 |
$460.54 |
| 87400 |
|
49 |
45 |
$450.26 |
| G2066 |
Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results |
27 |
26 |
$432.97 |
| 85347 |
|
45 |
38 |
$400.86 |
| 84445 |
|
24 |
24 |
$392.08 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
212 |
154 |
$389.05 |
| 85300 |
|
38 |
25 |
$376.50 |
| 86592 |
|
127 |
121 |
$374.01 |
| 20550 |
|
13 |
13 |
$355.90 |
| 80178 |
|
54 |
51 |
$355.53 |
| 88300 |
|
52 |
51 |
$350.65 |
| 95885 |
|
12 |
12 |
$349.99 |
| 87350 |
|
42 |
42 |
$346.46 |
| 99195 |
|
16 |
12 |
$339.73 |
| 84590 |
|
84 |
82 |
$333.45 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
174 |
163 |
$294.71 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
190 |
148 |
$290.39 |
| 82375 |
|
14 |
12 |
$284.57 |
| 86036 |
|
19 |
16 |
$282.19 |
| 86682 |
|
25 |
25 |
$279.16 |
| 88275 |
|
15 |
13 |
$277.25 |
| 97804 |
|
12 |
12 |
$258.48 |
| 88274 |
|
28 |
28 |
$257.45 |
| 27096 |
|
14 |
12 |
$240.94 |
| 84305 |
|
37 |
36 |
$223.84 |
| 84295 |
|
85 |
81 |
$220.08 |
| 80175 |
|
50 |
50 |
$216.47 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
22 |
16 |
$212.07 |
| 90785 |
|
182 |
172 |
$195.99 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
13 |
13 |
$181.16 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
28 |
14 |
$180.81 |
| 82668 |
|
31 |
29 |
$177.25 |
| 80156 |
|
13 |
13 |
$176.79 |
| Q0512 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period |
127 |
99 |
$158.40 |
| 94760 |
|
18 |
16 |
$154.78 |
| 83721 |
|
41 |
40 |
$154.59 |
| 88108 |
|
14 |
13 |
$154.48 |
| 85007 |
|
26 |
24 |
$147.10 |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
26 |
24 |
$136.45 |
| 87427 |
|
16 |
16 |
$133.83 |
| 84446 |
|
29 |
28 |
$130.06 |
| 82787 |
|
12 |
12 |
$128.55 |
| 94644 |
|
12 |
12 |
$121.90 |
| Q0511 |
Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period |
69 |
66 |
$112.08 |
| 87449 |
|
16 |
16 |
$111.64 |
| 85018 |
|
70 |
63 |
$111.39 |
| 85014 |
|
44 |
42 |
$99.59 |
| 84478 |
|
18 |
12 |
$98.82 |
| C1889 |
Implantable/insertable device, not otherwise classified |
240 |
234 |
$97.22 |
| 84080 |
|
24 |
24 |
$94.76 |
| 85303 |
|
12 |
12 |
$94.71 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
16 |
16 |
$92.59 |
| 87045 |
|
16 |
16 |
$83.22 |
| 85651 |
|
40 |
38 |
$82.10 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
14 |
13 |
$70.00 |
| 82960 |
|
12 |
12 |
$61.97 |
| 86707 |
|
12 |
12 |
$57.85 |
| 86308 |
|
12 |
12 |
$54.53 |
| 86352 |
|
18 |
14 |
$54.34 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
235 |
223 |
$51.30 |
| 85732 |
|
12 |
12 |
$49.91 |
| 83935 |
|
14 |
12 |
$46.90 |
| 0305 |
|
28 |
27 |
$43.65 |
| 84075 |
|
13 |
12 |
$41.02 |
| E0114 |
Crutches underarm, other than wood, adjustable or fixed, pair, with pads, tips and handgrips |
12 |
12 |
$29.00 |
| 84155 |
|
16 |
15 |
$26.31 |
| 87046 |
|
16 |
16 |
$25.79 |
| 0306 |
|
29 |
28 |
$20.07 |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
41 |
40 |
$17.65 |
| J0688 |
Injection, cefazolin sodium (hikma), not therapeutically equivalent to j0690, 500 mg |
13 |
13 |
$16.64 |
| J0153 |
Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds) |
12 |
12 |
$16.27 |
| Q0164 |
Prochlorperazine maleate, 5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
224 |
132 |
$15.07 |
| 0324 |
|
13 |
12 |
$11.24 |
| 0255 |
|
51 |
51 |
$10.88 |
| G2212 |
Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or qualified healthcare professional, with or without direct patient contact (list separately in addition to cpt codes 99205, 99215, 99483 for office or other outpatient evaluation and management services) (do not report g2212 on the same date of service as 99358, 99359, 99415, 99416). (do not report g2212 for any time unit less than 15 minutes) |
32 |
29 |
$4.12 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
21 |
15 |
$2.38 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
17 |
12 |
$0.95 |
| Q0247 |
Injection, sotrovimab, 500 mg |
29 |
29 |
$0.02 |
| 91306 |
|
47 |
47 |
$0.00 |
| 0300 |
|
12 |
12 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
236 |
211 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
236 |
211 |
$0.00 |
| 91300 |
|
12 |
12 |
$0.00 |
| A4565 |
Slings |
40 |
38 |
$0.00 |
| 91313 |
|
19 |
19 |
$0.00 |
| A4649 |
Surgical supply; miscellaneous |
37 |
16 |
$0.00 |